Prelude Therapeutics (PRLD) Expected to Announce Quarterly Earnings on Tuesday

Prelude Therapeutics (NASDAQ:PRLD) is projected to release its Q1 2025 earnings data before the market opens on Tuesday, May 6th. Analysts expect Prelude Therapeutics to post earnings of ($0.48) per share for the quarter.

Prelude Therapeutics (NASDAQ:PRLD) last announced its quarterly earnings results on Monday, March 10th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.11. The business had revenue of $4.00 million during the quarter. On average, analysts expect Prelude Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Prelude Therapeutics Stock Performance

NASDAQ:PRLD opened at $0.89 on Friday. The company has a 50-day moving average of $0.75 and a 200-day moving average of $1.00. Prelude Therapeutics has a 52 week low of $0.61 and a 52 week high of $6.80. The company has a market capitalization of $50.10 million, a price-to-earnings ratio of -0.50 and a beta of 1.35.

Insider Activity at Prelude Therapeutics

In other news, CEO Krishna Vaddi acquired 47,500 shares of the company’s stock in a transaction dated Wednesday, March 12th. The stock was bought at an average price of $0.71 per share, with a total value of $33,725.00. Following the completion of the acquisition, the chief executive officer now owns 1,214,775 shares in the company, valued at approximately $862,490.25. This represents a 4.07 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Andrew Combs bought 100,000 shares of the business’s stock in a transaction dated Tuesday, March 25th. The stock was purchased at an average price of $0.69 per share, with a total value of $69,000.00. Following the purchase, the insider now directly owns 480,123 shares of the company’s stock, valued at $331,284.87. The trade was a 26.31 % increase in their position. The disclosure for this purchase can be found here. Insiders bought 822,500 shares of company stock valued at $568,475 in the last ninety days. Insiders own 62.80% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. HC Wainwright reaffirmed a “buy” rating and set a $5.00 price objective on shares of Prelude Therapeutics in a report on Tuesday, April 8th. JMP Securities reaffirmed a “market outperform” rating and issued a $4.00 price target on shares of Prelude Therapeutics in a research note on Tuesday, April 29th.

About Prelude Therapeutics

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion.